{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T17:00:44Z","timestamp":1776445244309,"version":"3.51.2"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T00:00:00Z","timestamp":1717891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T00:00:00Z","timestamp":1717891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s40744-024-00683-0","type":"journal-article","created":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T16:01:23Z","timestamp":1717948883000},"page":"977-988","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacokinetics, Safety, and Immunogenicity of Intravenous and Subcutaneous Single-Dose QX002N Injection in Healthy Subjects: A Randomized, Open, Parallel, Single-Center, Phase I Study"],"prefix":"10.1007","volume":"11","author":[{"given":"Zhen-Wei","family":"Shen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai-Qi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting-Han","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7343-6996","authenticated-orcid":false,"given":"Gui-Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,9]]},"reference":[{"issue":"7422","key":"683_CR1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/nature11582","volume":"491","author":"L Jostins","year":"2012","unstructured":"Jostins L, et al. Host\u2013microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491(7422):119\u201324.","journal-title":"Nature"},{"issue":"6","key":"683_CR2","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, et al. The development of assessment of SpondyloArthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777\u201383.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"683_CR3","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978\u201391.","journal-title":"Ann Rheum Dis"},{"key":"683_CR4","doi-asserted-by":"crossref","unstructured":"Schinocca C., et al., Role of the IL-23\/IL-17 pathway in rheumatic diseases: an overview. Front Immunol. 2021;12:637829.","DOI":"10.3389\/fimmu.2021.637829"},{"issue":"12","key":"683_CR5","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1093\/rheumatology\/kep293","volume":"48","author":"P Hillyer","year":"2009","unstructured":"Hillyer P, et al. Investigating the role of the interleukin-23\/-17A axis in rheumatoid arthritis. Rheumatology. 2009;48(12):1581\u20139.","journal-title":"Rheumatology"},{"issue":"6","key":"683_CR6","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1002\/art.24568","volume":"60","author":"H Shen","year":"2009","unstructured":"Shen H, Goodall JC, Hill Gaston JS. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum. 2009;60(6):1647\u201356.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"683_CR7","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700\u201312.","journal-title":"Ann Rheum Dis"},{"issue":"10217","key":"683_CR8","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, et al. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet. 2020;395(10217):53\u201364.","journal-title":"Lancet"},{"issue":"10","key":"683_CR9","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/art.41042","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward MM, et al. 2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2019;71(10):1599\u2013613.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"683_CR10","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/art.40753","volume":"71","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, et al. Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: Sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors. Arthritis Rheumatol. 2019;71(4):599\u2013611.","journal-title":"Arthritis Rheumatol"},{"key":"683_CR11","unstructured":"FDA. COSENTYX\u00ae (secukinumab) for injection, for subcutaneous use, Initial U.S. 2015; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125504_S050_S051lbl.pdf#\/. Accessed 25 Apr 2024."},{"key":"683_CR12","unstructured":"FDA. TALTZ (ixekizumab) injection, for subcutaneous use, Initial U.S. 2016; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/125521s024lbl.pdf#\/. Accessed 25 Apr 2024."},{"issue":"1","key":"683_CR13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13075-019-1882-2","volume":"21","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019;21(1):111.","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"683_CR14","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1001\/jamadermatol.2022.2909","volume":"158","author":"ZZN Yiu","year":"2022","unstructured":"Yiu ZZN, et al. Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis. JAMA Dermatol. 2022;158(10):1131\u201341.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"683_CR15","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1002\/art.33507","volume":"64","author":"TJ Kenna","year":"2012","unstructured":"Kenna TJ, et al. Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive \u03b3\/\u03b4 T cells in patients with active ankylosing spondylitis. Arthritis Rheum. 2012;64(5):1420\u20139.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"683_CR16","doi-asserted-by":"publisher","first-page":"R95","DOI":"10.1186\/ar3370","volume":"13","author":"H Appel","year":"2011","unstructured":"Appel H, et al. Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther. 2011;13(3):R95.","journal-title":"Arthritis Res Ther"},{"key":"683_CR17","doi-asserted-by":"crossref","unstructured":"Wu M, et al. Pharmacokinetics, pharmacodynamics, safety, tolerability, and immunogenicity of the QX002N anti-IL-17 monoclonal antibody: a phase I, randomized, double-blind, single ascending dose study in healthy Chinese volunteers. Front Pharmacol. 2022;12:794054.","DOI":"10.3389\/fphar.2021.794054"},{"issue":"3","key":"683_CR18","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/j.1365-2036.2011.04946.x","volume":"35","author":"E Bultman","year":"2012","unstructured":"Bultman E, et al. Predictors of dose escalation of adalimumab in a prospective cohort of Crohn\u2019s disease patients. Aliment Pharmacol Ther. 2012;35(3):335\u201341.","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"683_CR19","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1002\/jcph.876","volume":"57","author":"G Bruin","year":"2017","unstructured":"Bruin G, et al. Population pharmacokinetic modeling of secukinumab in patients with moderate to severe psoriasis. J Clin Pharmacol. 2017;57(7):876\u201385.","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"683_CR20","doi-asserted-by":"publisher","first-page":"3804","DOI":"10.1007\/s12325-023-02575-1","volume":"40","author":"M Zheng","year":"2023","unstructured":"Zheng M, et al. Pharmacokinetics, safety, and efficacy of Ixekizumab in Chinese patients with moderate-to-severe plaque psoriasis: a phase 1, single- and multiple-dose study. Adv Ther. 2023;40(9):3804\u201316.","journal-title":"Adv Ther"},{"issue":"10378","key":"683_CR21","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","volume":"401","author":"AB Kimball","year":"2023","unstructured":"Kimball AB, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet. 2023;401(10378):747\u201361.","journal-title":"Lancet"},{"issue":"10163","key":"683_CR22","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","volume":"392","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde D, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018;392(10163):2441\u201351.","journal-title":"Lancet"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-024-00683-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-024-00683-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-024-00683-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T07:27:04Z","timestamp":1721460424000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-024-00683-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,9]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["683"],"URL":"https:\/\/doi.org\/10.1007\/s40744-024-00683-0","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,9]]},"assertion":[{"value":"25 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Zhen-Wei Shen, Kai-Qi Wu, Ting-Han Jin, Jie Zhao, Qi Jiang, Tong Guo, Min Fang, and Gui-Ling Chen have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The protocol, informed consent, and amendments were approved by the ethical Review Committee of Shulan (Hangzhou) Hospital(2021\u201326). All subjects signed written informed consent forms before participating. This study was conducted in accordance with the Good Practice for Quality Management of Clinical Trials (GCP), the current Declaration of Helsinki (2013), relevant regulations, and Ethics Committee reviews.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}